VC
ZSAN

Vivo Capital’s Zosano Pharma Corporation ZSAN Stock Holding History

Vivo Capital’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-141
Closed -$77K – 24
2016
Q4 		$77K Hold
141
– – 0.03% 24
2016
Q3 		$78K Hold
141
– – 0.02% 22
2016
Q2 		$125K Hold
141
– – 0.03% 22
2016
Q1 		$227K Buy
+141
New +$232K 0.06% 22

Other funds holding ZSAN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vivo Capital's ZSAN Position: Q1 2017 in Review

Vivo Capital sold out of Zosano Pharma Corporation (ZSAN) in Q1 2017, closing a stake of 141 shares — an estimated $77K sold.

Vivo Capital first reported a position in ZSAN in Q1 2016 and held it in 4 quarters. The position peaked at $227K in Q1 2016. 26 funds tracked by Wall St. Rank hold ZSAN as of Q1 2017.

  • Vivo Capital reported no remaining Zosano Pharma Corporation position as of Q1 2017 after selling out during the quarter.
  • Vivo Capital sold 141 Zosano Pharma Corporation shares in Q1 2017, an estimated $77K.
  • Vivo Capital first reported a position in Zosano Pharma Corporation in Q1 2016 and held it in 4 quarters.
  • Vivo Capital's Zosano Pharma Corporation position peaked at $227K in Q1 2016.
  • 26 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q1 2017.

Based on Vivo Capital's 13F filing for Q1 2017, filed 15 May 2017.